Comparing Doctors to Peers Doesn’t Make Them Hate Their Jobs and May Improve Quality of Care, New USC Schaeffer Study Finds
Researchers found that behavioral interventions aimed at improving performance can be designed to protect clinician job satisfaction and improve quality of care.
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Four Ways to Make Drug Price Negotiations Work for Everyone
The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
COVID-19’s Total Cost to the U.S. Economy Will Reach $14 Trillion by End of 2023
Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Schaeffer Research Director Testifies at Congressional Hearing on Biomedical Innovation and Patient Access
Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.
The Agency Keeping Alzheimer’s Drugs From Patients
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.
A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act
To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.
Medicare’s ‘Coverage with Evidence Development’: A Barrier to Patient Access and Innovation
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
Alternatives To The QALY For Comparative Effectiveness Research
We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.